JP2017533952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533952A5 JP2017533952A5 JP2017526594A JP2017526594A JP2017533952A5 JP 2017533952 A5 JP2017533952 A5 JP 2017533952A5 JP 2017526594 A JP2017526594 A JP 2017526594A JP 2017526594 A JP2017526594 A JP 2017526594A JP 2017533952 A5 JP2017533952 A5 JP 2017533952A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- pharmaceutical composition
- composition according
- amine
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 206010005003 Bladder cancer Diseases 0.000 claims 16
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 201000005112 urinary bladder cancer Diseases 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 150000003141 primary amines Chemical class 0.000 claims 6
- 150000003335 secondary amines Chemical class 0.000 claims 6
- 150000003512 tertiary amines Chemical class 0.000 claims 6
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims 5
- 229960003749 ciclopirox Drugs 0.000 claims 4
- 229960004375 ciclopirox olamine Drugs 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 229910001415 sodium ion Inorganic materials 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- NTKBXPWLNROYPE-UHFFFAOYSA-N (2-cyclohexyl-4-methyl-6-oxopyridin-1-yl)oxymethyl dihydrogen phosphate Chemical compound OP(=O)(O)OCON1C(=O)C=C(C)C=C1C1CCCCC1 NTKBXPWLNROYPE-UHFFFAOYSA-N 0.000 claims 1
- DEBBIUUNXLFGRA-UHFFFAOYSA-N 6-cyclohexyl-1-hydroxy-4-methyl-2H-pyridine Chemical compound CC1=CCN(O)C(C2CCCCC2)=C1 DEBBIUUNXLFGRA-UHFFFAOYSA-N 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 102000008201 Lamin Type A Human genes 0.000 claims 1
- 108010021099 Lamin Type A Proteins 0.000 claims 1
- 108010070047 Notch Receptors Proteins 0.000 claims 1
- 102000005650 Notch Receptors Human genes 0.000 claims 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
- 230000018199 S phase Effects 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 0 CC(C**(C)OC*P([*+]=C)(OC(C)(C)C)=O)ON(C(C1CCCCC1)=CC(C)=C1)C1=O Chemical compound CC(C**(C)OC*P([*+]=C)(OC(C)(C)C)=O)ON(C(C1CCCCC1)=CC(C)=C1)C1=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078069P | 2014-11-11 | 2014-11-11 | |
| US62/078,069 | 2014-11-11 | ||
| US201562134747P | 2015-03-18 | 2015-03-18 | |
| US62/134,747 | 2015-03-18 | ||
| PCT/US2015/059955 WO2016077346A1 (en) | 2014-11-11 | 2015-11-10 | Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533952A JP2017533952A (ja) | 2017-11-16 |
| JP2017533952A5 true JP2017533952A5 (enExample) | 2018-12-20 |
Family
ID=55954945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526594A Pending JP2017533952A (ja) | 2014-11-11 | 2015-11-10 | シクロピロクス、シクロピロクスオラミン又はシクロピロクスプロドラッグを用いる、膀胱癌の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170304329A1 (enExample) |
| EP (1) | EP3217980B1 (enExample) |
| JP (1) | JP2017533952A (enExample) |
| CN (2) | CN116687941A (enExample) |
| DK (1) | DK3217980T3 (enExample) |
| ES (1) | ES2836208T3 (enExample) |
| HR (1) | HRP20201893T1 (enExample) |
| HU (1) | HUE052670T2 (enExample) |
| PL (1) | PL3217980T3 (enExample) |
| PT (1) | PT3217980T (enExample) |
| RS (1) | RS61222B1 (enExample) |
| WO (1) | WO2016077346A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11753379B2 (en) | 2018-05-30 | 2023-09-12 | Clariant International Ltd | Process for forming 2-hydroxypyridine-1-oxide or derivatives thereof |
| CN113194945B (zh) * | 2018-08-23 | 2024-07-23 | 佩勒梅德有限公司 | 环吡酮的抑制hbv核心组装的用途 |
| WO2021078937A1 (en) * | 2019-10-25 | 2021-04-29 | Deutsches Krebsforschungszentrum | Treatment of stat3 related diseases by iron chelators |
| EP4193989A1 (en) | 2021-12-09 | 2023-06-14 | Atlas Molecular Pharma, S.L. | A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU754965B2 (en) | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| AU2003251875A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| WO2010048712A1 (en) | 2008-10-31 | 2010-05-06 | University Health Network | Ciclopirox and cytarabine for the treatment of leukemic disorders |
| WO2011153197A1 (en) * | 2010-06-01 | 2011-12-08 | Biotheryx, Inc. | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
| PL2646035T3 (pl) * | 2010-12-02 | 2016-08-31 | Univ Kansas | Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne |
-
2015
- 2015-11-10 DK DK15859268.3T patent/DK3217980T3/da active
- 2015-11-10 PT PT158592683T patent/PT3217980T/pt unknown
- 2015-11-10 RS RS20201438A patent/RS61222B1/sr unknown
- 2015-11-10 HU HUE15859268A patent/HUE052670T2/hu unknown
- 2015-11-10 WO PCT/US2015/059955 patent/WO2016077346A1/en not_active Ceased
- 2015-11-10 ES ES15859268T patent/ES2836208T3/es active Active
- 2015-11-10 CN CN202310102470.8A patent/CN116687941A/zh active Pending
- 2015-11-10 HR HRP20201893TT patent/HRP20201893T1/hr unknown
- 2015-11-10 JP JP2017526594A patent/JP2017533952A/ja active Pending
- 2015-11-10 EP EP15859268.3A patent/EP3217980B1/en active Active
- 2015-11-10 CN CN201580061284.8A patent/CN107206012A/zh active Pending
- 2015-11-10 PL PL15859268.3T patent/PL3217980T3/pl unknown
- 2015-11-10 US US15/526,164 patent/US20170304329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11878046B2 (en) | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | |
| CN105814028B (zh) | 作为免疫调节剂的1，2，4‑*二唑衍生物 | |
| ES2661850T3 (es) | Moduladores de receptores del tipo toll | |
| JP2013509429A5 (enExample) | ||
| WO2017180917A3 (en) | Lipid compositions and their uses for intratumoral polynucleotide delivery | |
| US20210070806A1 (en) | Cyclic cell-penetrating peptides with one or more hydrophobic residues | |
| JP2014520120A5 (enExample) | ||
| CA2818990C (en) | Designed repeat proteins binding to serum albumin | |
| WO2013004716A9 (en) | Peptide beads | |
| CN105418610B (zh) | 一种10‑羟基吴茱萸碱类抗肿瘤化合物及其制备方法和应用 | |
| WO2016134301A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2017521486A5 (enExample) | ||
| EP2305642A3 (en) | Bis(thio-hydrazide amide) salts for treatment of cancers | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2008509166A5 (enExample) | ||
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2012532874A5 (enExample) | ||
| ZA202301784B (en) | Crf2 receptor agonists and their use in therapy | |
| JP2018531987A5 (enExample) | ||
| TW202500573A (zh) | 細胞穿透肽序列 | |
| NZ593524A (en) | A nonapeptide with anti-tumour activity | |
| JP2012529293A5 (enExample) | ||
| MX383762B (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| MX390044B (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. |